Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
300 participants
OBSERVATIONAL
2016-10-05
2021-10-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Recent improvements in technology allow high doses of radiation to be delivered to the prostate in less days with lower doses to surrounding healthy tissues, trying to reduce side effects.
This study is being proposed to evaluate the use of moderate hypofractionated volumetric radiotherapy in localized prostate cancer patients and assessing treatment -related later adverse events using the CTCAE 4.0
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Hypofractionated Radiotherapy (55 Gy/16 Fractions/4 Weeks) for Localized Prostate Cancer
NCT00129025
Multicenter Study of Hypofractionated Postoperative Radiotherapy in Patients Diagnosed With Prostate Carcinoma
NCT04484038
Short-term High Precision Radiotherapy for Early Prostate Cancer With Concomitant Boost on the Dominant Lesion
NCT01913717
Hypofractionated Radiotherapy in Prostate Cancer Patients Aged 75 Years or Older.
NCT04535908
A First Step Towards Ultra-hypofractionation for Unfavourable Intermediate and High-risk Prostate Cancer
NCT05361902
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
It is thought that this regimen will produce comparable findings and would result in substantial health care cost savings, as well as, be more convenient for patients.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Hypofractionated volumetric radiotherapy in 20 fractions
Hypofractionated radiotherapy at 3 Gy per fraction for localized prostate cancer.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Performance Status 0-2
* Signed informed consent form
Exclusion Criteria
* Anticoagulant treatment, individual assessment of antiplatelet therapy
* Previous pelvic radiotherapy
* Previous surgery for prostate cancer
* Previous transurethral resection of the prostate
* History of Crohn's Disease or Ulcerative Colitis
* Antecedents of rectal fistulas in the last 10 years
* Previous significant urinary obstructive symptoms
* Previous chemotherapeutic treatments
* Non-compliance with constraints established in this protocol (see special section
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Consorci Sanitari de Terrassa
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Nicolas Feltes
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
NICOLAS FELTES
Role: STUDY_DIRECTOR
Consorci Sanitari de Terrassa
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital de Terrassa
Terrassa, Barcelona, Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ONCORTCST2019-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.